title: Nutritional status and bioelectrical phase angle assessment in adult Crohn disease patients receiving anti-TNFα therapy.
abstract: BACKGROUND
  Altered body composition is frequently observed in Crohn's disease (CD) patients.
  
  
  OBJECTIVE
  To investigate the nutritional status, and the effect of different therapeutic regimes in adult CD patients.
  
  
  METHODS
  Fat free mass (FFM) and BIA-derived phase angle (PhA) were assessed in 45 CD patients, 22 on conventional therapy (CT) and 23 on maintenance therapy with infliximab (MT). Nutritional status was also assessed in 12 CD patients before and following the induction protocol with infliximab. BIA data of CD patients were compared with those of 20 healthy asymptomatic volunteers. In CD patients C Reactive Protein (CRP) and albuminaemia dosage were obtained.
  
  
  RESULTS
  The mean values of PhA and of FFM were significantly lower in CT patients when compared with control group and MT patients. Following infliximab treatment FFM increased, although not significantly, while mean phase angle value significantly increased from 4.6±0.3 to 6.2±0.4 (p<0.05). CRP was significantly lower in MT patients compared to that in CT patients.
  
  
  CONCLUSIONS
  CD patients on conventional therapy showed a lower FFM and a lower mean phase angle score compared to those on infliximab therapy. Following infliximab treatment the mean phase angle score normalized. PhA is a reliable nutritional indicator in IBD patients and could be considered as an additional tool for assessing response to treatment.
authors.affiliation: Unit of Digestive Disease of Campus Bio Medico University of Rome, Italy. Electronic address: s.emerenziani@unicampus.it.
authors.forename: Sara
authors.initials: S
authors.lastname: Emerenziani
authors.affiliation: Department of Systems Medicine, Università "Tor Vergata" of Rome, Italy.
authors.forename: Livia
authors.initials: L
authors.lastname: Biancone
authors.affiliation: Unit of Digestive Disease of Campus Bio Medico University of Rome, Italy.
authors.forename: Michele Pier Luca
authors.initials: MPL
authors.lastname: Guarino
authors.affiliation: Unit of Digestive Disease of Campus Bio Medico University of Rome, Italy.
authors.forename: Paola
authors.initials: P
authors.lastname: Balestrieri
authors.affiliation: Department of Systems Medicine, Università "Tor Vergata" of Rome, Italy.
authors.forename: Elisa
authors.initials: E
authors.lastname: Stasi
authors.affiliation: Unit of Digestive Disease of Campus Bio Medico University of Rome, Italy.
authors.forename: Mentore
authors.initials: M
authors.lastname: Ribolsi
authors.affiliation: Unit of Digestive Disease of Campus Bio Medico University of Rome, Italy.
authors.forename: Maria Paola
authors.initials: MP
authors.lastname: Rescio
authors.affiliation: Unit of Digestive Disease of Campus Bio Medico University of Rome, Italy.
authors.forename: Annamaria
authors.initials: A
authors.lastname: Altomare
authors.affiliation: Unit of Digestive Disease of Campus Bio Medico University of Rome, Italy.
authors.forename: Silvia
authors.initials: S
authors.lastname: Cocca
authors.affiliation: Department of Systems Medicine, Università "Tor Vergata" of Rome, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Pallone
authors.affiliation: Unit of Digestive Disease of Campus Bio Medico University of Rome, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Cicala
mesh_terms: D000328:Adult; D001823:Body Composition; D015992:Body Mass Index; D016022:Case-Control Studies; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy*; D017097:Electric Impedance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D007558:Italy; D008297:Male; D044342:Malnutrition / Q000209:etiology*; D008875:Middle Aged; D015596:Nutrition Assessment; D009752:Nutritional Status; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab
keywords: Biologic and conventional therapies; Body composition; Crohn’s disease; Malnutrition; Nutritional status